NBD AI Bulletin,Shenzhen Salubris Pharmaceuticals Co., Ltd. (the Company, SZ 002294, closing price: 21.0 yuan) announced on June 9 that the Company's controlling shareholder, Salubris Pharmaceuticals Limited, on June 8 released 54 million shares of the Company originally pledged to Tibet Trust Co., Ltd., representing 7.85% of its holding. On the same day, another 2.55 million shares were pledged.

As of the date of this announcement, Salubris Pharmaceuticals Limited holds 687.58018 million shares of the Company, accounting for 65.73% of the total number of shares of the Company.

According to the 2019 Annual Report, Shenzhen Salubris Pharmaceuticals Co., Ltd.'s main businesses are pharmaceutical and medical devices, accounting for 98.22% and 1.54% of revenue, respectively.

Shenzhen Salubris Pharmaceuticals Co., Ltd.'s chairman is Ye Chenghai, male, 77, Chinese national, with a Bachelor's degree. The general manager of Shenzhen Salubris Pharmaceuticals Co., Ltd., is Kevin Sing Ye, male, 46, U.S. citizen, MBA, Yale University.

(By Li Menglin)

Disclaimer: This article is for informational purposes only and does Not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.